Lexaria Bioscience Corp. LEXX Archives - Page 24 of 39

WednesdayAug 10, 2022 12:34 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension. According to the update, the FDA confirmed agreement with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. This is advantageous because the abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) NDA pathway. “We are very pleased to have received…

TuesdayAug 09, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Generation of CBD Products Under “Ko” Branding by Japanese Licensee Premier Wellness Science Co., Ltd.

Lexaria’s patented DehydraTECH(TM) has 26 granted patents worldwide, including four in Japan Lexaria stands to gain substantial revenue through the licensing of DehydraTECH technology across minimum quarterly payments for license use by Premier and royalties for products sold By 2028, the CBD market is expected to reach US$47.22 billion, driven by increased demand for CBD use in health and wellness Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms and developer of the patented DehydraTECH(TM) technology for the delivery of fat-soluble molecules and drugs, has announced that Japanese Licensee, Premier Wellness Science Co., Ltd., has officially launched the…

TuesdayAug 02, 2022 1:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Helping Innovators of Today, Leaders of Tomorrow

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) patented DehydraTECH(TM) has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. Studies have also demonstrated DehydraTECH’s ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances, with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery. “DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a…

WednesdayJul 27, 2022 12:04 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing with its DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been completed in its multi-week human clinical hypertension study HYPER-H21-4. According to the update, no serious adverse events have been reported as a result of the dosing. “We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this…

TuesdayJul 26, 2022 1:23 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its exclusive* Japanese licensee, Premier Wellness Science Co. Ltd., officially launched the first generation of its new cannabidiol (“CBD”) products under the brand “Ko.” According to the update, the brand was launched for the Japanese consumer market on July 21, 2022. Premier will create its own e-commerce infrastructure and digital marketing campaigns in collaboration with its parent company, Premier Anti-Aging Co. Ltd., which is listed on the Tokyo Stock Exchange (4934:JP). The Ko brand will contain CBD and other botanical extracts and is focused on…

MondayJul 25, 2022 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent

Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency “We are extremely pleased to have received our first patent protecting our…

WednesdayJul 20, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pending Start of Human Nicotine Study, NIC-H22-1, Leveraging Fast-Growing Global Nicotine Pouches Market

Lexaria Bioscience Corp. expects the upcoming human nicotine study to produce evidence that its patented DehydraTECH(TM) technology can enhance oral-tissue absorption with reduced negative experiences Data collected from animal study NIC-A21-1 showed that DehydraTECH enhanced oral nicotine pouches delivered peak nicotine levels in the bloodstream of animals 10x to 20x faster than the control The global nicotine pouches market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, being one of the fastest growing segments in the nicotine industry Lexaria's pipeline addresses serious unmet patient or consumer needs with greater market potential, addressing…

MondayJul 18, 2022 12:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently entered into agreements with beverage developer BevNology. “The BevNology collaboration not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta…. The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer-packaged-goods brands. Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility,” a recent article reads.…

MondayJul 18, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD…

ThursdayJul 14, 2022 1:03 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX